Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe

We measured early 2016/17 season influenza vaccine effectiveness (IVE) against influenza A(H3N2) in Europe using multicentre case control studies at primary care and hospital levels. IVE at primary care level was 44.1%, 46.9% and 23.4% among 0-14, 15-64 and ≥ 65 year-olds, and 25.7% in the influenza...

Full description

Saved in:
Bibliographic Details
Published inEuro surveillance : bulletin européen sur les maladies transmissibles Vol. 22; no. 7; p. 1
Main Authors Kissling, Esther, Rondy, Marc
Format Journal Article
LanguageEnglish
Published Sweden Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS) 16.02.2017
European Centre for Disease Prevention and Control (ECDC)
Subjects
Adolescent
Adult
Aged
Aged, 80 and over
Case-Control Studies
Child
Child, Preschool
Effectiveness
Europe - epidemiology
European Union
Female
Hospitals
Humans
Infant
Infant, Newborn
Influenza
Influenza A Virus, H3N2 Subtype - immunology
Influenza A Virus, H3N2 Subtype - isolation & purification
Influenza Vaccines - administration & dosage
Influenza Vaccines - immunology
Influenza, Human - epidemiology
Influenza, Human - prevention & control
Influenza, Human - virology
Middle Aged
Outcome Assessment (Health Care)
Pandemics - prevention & control
Population Surveillance
Primary Health Care
Rapid Communication
Seasons
Sensitivity and Specificity
Sentinel Surveillance
Vaccination - statistics & numerical data
Vaccines
Young Adult
Europe
influenza
vaccine effectiveness
SARI
influenza like illness
vaccines
ILI
severe acute respiratory infection
immunisation
Online AccessGet full text

Cover

More Information
Summary:We measured early 2016/17 season influenza vaccine effectiveness (IVE) against influenza A(H3N2) in Europe using multicentre case control studies at primary care and hospital levels. IVE at primary care level was 44.1%, 46.9% and 23.4% among 0-14, 15-64 and ≥ 65 year-olds, and 25.7% in the influenza vaccination target group. At hospital level, IVE was 2.5%, 7.9% and 2.4% among ≥ 65, 65-79 and ≥ 80 year-olds. As in previous seasons, we observed suboptimal IVE against influenza A(H3N2).
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Correspondence: Esther Kissling (e.kissling@epiconcept.fr)
ISSN:1560-7917
1025-496X
1560-7917
DOI:10.2807/1560-7917.ES.2017.22.7.30464